Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, Rosell, R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. EUROPEAN JOURNAL OF CANCER. 2021; 159DOI:10.1016/j.ejca.2021.09.039. PMID:34763195. IF:10.002(Q1/2D).

Osuna-Gomez, R, Arqueros, C, Galano, C, Mulet, M, Zamora, C, Barnadas, A, Vidal, S. Effector Mechanisms of CD8+HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy. Cancers. 2021; 13(24)DOI:10.3390/cancers13246167. PMID:34944786. IF:6.575(Q1/3D).

Rubio-Viqueira, B, Tarruella, MM, Lazaro, M, Estevez, SV, Cordoba-Ortega, JF, Maiques, IM, Gonzalez, JG, Cordellat, AB, Valdivia-Bautista, J, Arenas, CG, Torres, JMS. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study. Lung Cancer Management. 2021; 10(4)DOI:10.2217/lmt-2021-0008. PMID:34899993. IF:(Q/D).

Caamano, AG, Vicente, AMGM, Maroto, P, Antolin, AR, Sanz, J, Gonzalez, MAV, Climent, MA. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group. Current Oncology. 2021; 28(6)DOI:10.3390/curroncol28060428. PMID:34940067. IF:3.109(Q3/8D).